Metraipolis › archive › dc_58f60ec0a0eb

From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies — Europe PMC PMID:41900834

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41900834
DOI
10.3390/pharmaceutics18030347
License (as archived)
solo-consultazione
Archived
2026-11-04T13:18:30.869Z
SHA-256 of the archived text
7efb53019f1da97669a2a05a39034213283139412c85a8ec64f0cdb401207097
Stable URL of this page
https://metraipolis.com/documento/dc_58f60ec0a0eb

How to cite

From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies — Europe PMC PMID:41900834 — Europe PMC (en), https://europepmc.org/article/MED/41900834 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_58f60ec0a0eb (Metraipolis archive dc_58f60ec0a0eb, sha256 7efb53019f1da97669a2a05a39034213283139412c85a8ec64f0cdb401207097)
BibTeX
@misc{dc58f60ec0a0eb,
  title = {From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies — Europe PMC PMID:41900834},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41900834},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_58f60ec0a0eb; sha256 7efb53019f1da97669a2a05a39034213283139412c85a8ec64f0cdb401207097},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41900834. Agents can read the archived copy with the MCP tool read_document.